Adagio Therapeutics (ADGI) Shares Are Up 80% Since Friday. Here's Why
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adagio Therapeutics (ADGI) Stock Now Up 70%, Stifel Says Merck's (MRK) Molnupiravir is not a Competitive Threat to ADG20
November 29, 2021 11:08 AM ESTAdagio Therapeutics (NASDAQ: ADGI) stock is up around 70% today as investors continue to bet that alternative cures are needed and vaccines alone are unlikely to sufficiently address the COVID-19 pandemic.
Adagio shares soared in pre-open Monday after the company said its lead candidate ADG20 will retain activity against the new COVID variant Omicron.
None of the mutations present in the spike protein of the Omicron variant have been... More
Adagio Therapeutics (ADGI) Reports That None of the Mutations Present in SARS-CoV-2 Variant, Omicron, Are Associated with Escape from ADG20 Neutralization In Vitro
November 29, 2021 6:31 AM ESTAdagio Therapeutics, Inc., (Nasdaq: ADGI) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today provided information related to the potential of its lead SARS-CoV-2 antibody, ADG20, to address the Omicron SARS-CoV-2 variant, and other known variants of concern. ADG20 is an investigational monoclonal antibody (mAb) product candidate designed to provide broad and potent neutralizing activity against SARS-CoV-2, including variants of concern, for the prevention and treatment of COVID-19 with potential duration of protection for up to one year in a single... More
